HIMS — Hims & Hers Health, Inc.

Is HIMS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Oversold As of August 19, 2026

Hims & Hers Health, Inc. (HIMS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $31.09. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Hims & Hers Health, Inc. (HIMS) combines a recognizable DTC brand with subscription-like service offerings and multi-product revenue streams, giving it potential for steady unit economics if customer acquisition remains efficient. Recent negative headlines and an FTC lawsuit elevate regulatory and reputational risk, creating uncertainty around future marketing practices and data monetization. Management’s public defense helps stabilize near-term sentiment but does not eliminate legal exposure or the potential for increased compliance costs. Given neutral macro conditions and selective interest in growth names, outcomes in the next month will likely be driven by legal developments, customer metrics (CAC and churn), and any disclosure on regulatory risk mitigation.

Key factors

  • Direct-to-consumer brand with multi-product platform (telehealth, prescription care, consumer wellness) supporting recurring revenue and potential cross-sell
  • Recent FTC allegations and negative news flow increase regulatory and reputational scrutiny for data/privacy practices
  • Management response denying wrongdoing and emphasizing expanded patient access reduces near-term information asymmetry but outcome uncertainty remains
  • Macro and market backdrop is neutral with selective interest in growth names — limits broad-sector tailwinds or headwinds in the short window
  • Exposure to digital-marketing channels and third-party ad partners drives customer acquisition efficiency but creates vulnerability if ad-driven tactics are constrained
  • Opportunity to expand service offerings and pharmacy/fulfillment integration could lift lifetime value if regulatory/compliance risks are managed

Risks

  • FTC enforcement or litigation outcomes that result in fines, restrictions on data usage, or limits on ad-driven acquisition
  • Reputational damage leading to higher churn and lower new-customer conversion rates
  • Increased compliance and legal costs that compress margins and slow investments in growth initiatives
  • Competitive pressure from established telehealth players, pharmacies, and vertically integrated incumbents (including retail entrants into MA/benefits)
  • Payer dynamics and potential reimbursement or formulary shifts that reduce monetization of certain service lines
  • Limited visibility into near-term financials (no EDGAR comparison provided) increases forecasting uncertainty

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for HIMS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.